PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON Russian patent published in 2020 - IPC A61K47/61 A61K38/26 A61P3/10 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a GLP-1/glucagon agonist conjugate and Z-L¹-L²-L-Y-R²⁰ linker, where Y is a GLP-1/glucagon agonist fragment; and -L is a linker moiety of formula (Ib) or a moiety of formula (Ic), wherein the dashed line indicates attachment to one of the amino groups of the GLP-1/glucagon agonist fragment by forming an amide linkage, and Z is hydrogel based on cross-linked hyaluronic acid, in which 0.05 to 20 % of the monomer disaccharide links are cross-linked by a cross-linking agent; and from 0.2 to 8.5 % monomeric disaccharide links contain groups L¹-L²-L-Y-R²⁰.

,

EFFECT: present invention also relates to pharmaceutical compositions containing said prodrugs, as well as to use thereof as a medicinal agent for treating or preventing diseases or disorders which can be cured by GLP-1/glucagon agonist.

21 cl, 5 dwg, 5 tbl, 29 ex